Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Influence of Antihypertensive Drug Therapy on Sleep Pattern and Sleep Apnea Activity

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sleep apnea, which affects 10% of men in the mean age group, is a common illness, and arterial hypertension one of its early symptoms. For the large group of, mainly young, patients with mild to moderate sleep apnea and arterial hypertension it is important to have a drug treatment available which will effectively control blood pressure without exacerbating symptoms of sleep apnea. We studied the effects of antihypertensive agents on blood pressure, sleep and sleep apnea in a randomized double-blind study of 24 patients with a sleep apnea acitivty of more than 10 apnea phases per hour of sleep and arterial hypertension with diastolic blood pressure values in the sitting position ≧ 95 mm Hg. Mean age was 51 (range: 33–69) years, mean body mass index 31.4 (24.9–40.6) kg/m2. The study protocol envisaged two baseline measurements in the sleep laboratory, after which the medication was administered for 8 days. On the last 2 days of the treatment, polysomnographic leads were once again recorded in the sleep laboratory. The patients received either the β-blocker metoprolol (1 × 100 mg/day) or the angiotensin-converting enzyme inhibitor cilazapril (1 × 2.5 mg/day). Systolic and diastolic blood pressure were decreased by both substances as expected. Total sleep time was 358 (233–425) min vs. 332 (255–383) min in the metoprolol group and 368 (295–424) min vs. 341 (265–434) min in the cilazapril group which is statistically not different between the two groups nor between the proportions of non-REM and REM sleep. Sleep apnea activity was 40 (15–91) vs. 26 (0–57) apneas/h of sleep in the metoprolol group and 40 (12–84) vs. 27 (0–72) apneas/h in the cilazapril group, which is a significant decrease for both groups (p < 0.01). Further investigation has to explore detailed blood pressure analysis by invasive means in dependence on sleep stages and nocturnal breathing disorders under antihypertensive treatment. For the large group of patients with nocturnal breathing disorders, the knowledge of possible side effects of an antihypertensive therapy is essential.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1991
          1991
          12 November 2008
          : 78
          : 2
          : 124-130
          Affiliations
          Medical Outpatient Department (Prof. P. von Wichert), Philipps-Universität Marburg, FRG
          Article
          174776 Cardiology 1991;78:124–130
          10.1159/000174776
          1829981
          © 1991 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Clinical Pharmacology

          Comments

          Comment on this article